(NYSE: HAE) Haemonetics's forecast annual revenue growth rate of 3.65% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 15.93%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 61.07%.
Haemonetics's revenue in 2026 is $1,318,275,000.On average, 12 Wall Street analysts forecast HAE's revenue for 2026 to be $61,853,366,850, with the lowest HAE revenue forecast at $59,715,684,750, and the highest HAE revenue forecast at $64,595,176,500. On average, 11 Wall Street analysts forecast HAE's revenue for 2027 to be $65,478,132,150, with the lowest HAE revenue forecast at $62,364,551,700, and the highest HAE revenue forecast at $69,288,782,850.
In 2028, HAE is forecast to generate $70,171,738,500 in revenue, with the lowest revenue forecast at $66,825,801,300 and the highest revenue forecast at $74,400,631,350.